Jair Isai Ortega-Gaxiola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jair Isai Ortega-Gaxiola has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Adrian L. Orjuela
Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Panama City 0843-01103, Panama
1 shared publication - Andrés Amaya-Flórez
Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior S/N, Ciudad de México 04510, Coyoacán, Mexico
1 shared publication - Antonino Arenaza-Corona
Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad de México, CP 04510, Mexico
1 shared publication - David Morales-Morales
Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior S/N, Ciudad de México 04510, Coyoacán, Mexico
1 shared publication - Jordi Ruiz-Galindo
Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior S/N, Ciudad de México 04510, Coyoacán, Mexico
1 shared publication - Jorge Alí-Torres
Departamento de Química, Universidad Nacional de Colombia-Sede Bogotá, Bogotá 111321, Colombia
1 shared publication
Latest Publications
- Open Access
- 2 December 2025
- Published by MDPI AG in Inorganics
- Vol. 13 (12) , 398
Preliminary Study of the Cytotoxic Activity of Pd(II) and Pt(II) Complexes Bearing P-N ligands Derived from Aminoalcohols
Iminophosphine ligands find extensive applications in homogeneous catalysis; however, their potential antitumor activity is currently being explored. Including biologically active moieties, such as aminoalcohols, could enhance this activity further. Therefore, we have synthesised a novel series of Pd(II) and Pt(II) iminophosphine complexes incorporating aminoalcohols as biologically active moieties to explore the potential of enhancing this activity. The series of Pd(II) complexes includes complexes 2a, 2f, and 2h, which were previously reported by our research group as catalysts in Suzuki–Miyaura cross-coupling reaction in aqueous media. Besides their complete characterisation, some structures have been unequivocally corroborated by single-crystal X-ray diffraction (SC-XRD). To evaluate the cytotoxic potential of the complexes, a preliminary in vitro study was conducted on different cancerous cell lines, including using COS-7 cells as a healthy cell line. Notably, complexes 2e, 2f, and 3b exhibited selectivity towards human chronic myelogenous leukaemia (K562), demonstrating IC50 values of 7.73 ± 1.4 µM, 8.53 ± 1.9 µM, and 8.83 ± 1.5 µM, respectively. Remarkably, the selectivity of these complexes surpassed that of cisplatin. Furthermore, in silico analysis indicated a higher binding energy of these complexes to DNA when compared to cisplatin.
- 2 December 2025
- Published by MDPI AG in Inorganics
- Vol. 13 (12) , 398
Open AccessPreliminary Study of the Cytotoxic Activity of Pd(II) and Pt(II) Complexes Bearing P-N ligands Derived from Aminoalcohols
Iminophosphine ligands find extensive applications in homogeneous catalysis; however, their potential antitumor activity is currently being explored. Including biologically active moieties, such as aminoalcohols, could enhance this activity further. Therefore, we have synthesised a novel series of Pd(II) and Pt(II) iminophosphine complexes incorporating aminoalcohols as biologically active moieties to explore the potential of enhancing this activity. The series of Pd(II) complexes includes complexes 2a, 2f, and 2h, which were previously reported by our research group as catalysts in Suzuki–Miyaura cross-coupling reaction in aqueous media. Besides their complete characterisation, some structures have been unequivocally corroborated by single-crystal X-ray diffraction (SC-XRD). To evaluate the cytotoxic potential of the complexes, a preliminary in vitro study was conducted on different cancerous cell lines, including using COS-7 cells as a healthy cell line. Notably, complexes 2e, 2f, and 3b exhibited selectivity towards human chronic myelogenous leukaemia (K562), demonstrating IC50 values of 7.73 ± 1.4 µM, 8.53 ± 1.9 µM, and 8.83 ± 1.5 µM, respectively. Remarkably, the selectivity of these complexes surpassed that of cisplatin. Furthermore, in silico analysis indicated a higher binding energy of these complexes to DNA when compared to cisplatin.